【導(dǎo)讀】--. --. TechnologyCo.，Ltd. 一﹑Briefintroduction. （一）Ourpany. （一）Majorproducts. （三）Manufacturing. 四﹑Businessoperation. majorproducts. （二）Financialcondition. （三）Capitalrunning. （四）Will-beinvestmentand. expansionprojects. 五、Businessculture. --. --. Text. 一、Briefintroduction. （一）Ourpany. medicine,etc.than200patterns). --. --. Co,.Ltd.Marketingcentre. centre. Boardofdirectors. Supervisors’meeting. CEO. AssistantCEONo.1. Business. designingcentre. Executive. office. Man. -powerdepartment. Transportation. team. Manufacturing. centre. President. AssistantCEONo.2. AssistantCEONo.4. AssistantCEONo.3. Experts. group. Auditing. office. Financial. management. dep.New. Stockholders’meeting. --. --. ZhiLingzhang------42year-old.Hehasgraduated. technology.MinyiXia------38year-old,standingvicepresid

　　

【正文】 ur craftwork causes no harm with environment and which has been examined by relative departments without any bad records. As for environmental prevention, the following countermeasures are adopted: 1. A sewage settling station of 500 thousand tonnages has been established。 2. A set of dust eliminating equipment of 300 thousand tonnages has been established. The percentage we spend in environmental prevention is 5% of the total cost of production. We possess 4 types of capsule and one type of granule with which craftworks were developed by ourselves and patented. Furthermore, we have purchased relative equipments and construction facilities to establish a thorough assembly line. (四 ) Researching and developing of our products 1. Organization, development and quality with department of developing new products We have established new drug researching and developing centre which is the most important part for our petition power and which is in charge of researches of preGLP craftwork and dose posing. 2. Development direction and research preference of our major techniques, List and progress rate of our underdeveloping products Major products under developing are hepatitis B and C genechecking chip, Xinlutai capsule and Xiecaoyou gelatin pearl. Our researching subjects are focused upon heart and brain blood vessel disease and rare pediatric medicines. 3. Service and support of technical department for manufacturing and sale departments We initiate technical cooperation and exchange with scientific institutions such as Jining Chinese Medicine Institute and Hubei Chinese Medicine Institute and thus provide strong support to our manufacturing craftwork and technique. Tasks of the above institutions are to provide guidance of manufacturing technique and settlement and perfection of manufacturing puzzles. 4. Motivation system and effect with researching staff We have formed an annualsalary issuing policy for major researching staff with whom 80% of payments are firstly issued and the rest of 20% are paid in accordance with their yearend performance review. Besides, we have established outstanding acplishment award which is rewarded by board meeting in terms of rate of progress being achieved with a given product. 四 . Business operation (一 ) Marketing patterns for major products Our leading products are tens of variety. Zhiqi granule, for instance, is the first national approved lead eliminant. According to its characteristic, we have designed a whole set of unique marketing operation formula with which various marketing strategies can be chosen in accordance with different feature, experience, resource volume and capability of individual sale agents. What′ s more, we have sent out marketing missioners of rich experience to help sale agents. Our marketing patterns are: 1. Hospital marketing 2. Meeting marketing 3. OTC marketing (二 ) Financial condition Financial indexes of our pany kept increasing for sequential fiscal years. From 2020 to 2020, our major business ine and total capital are RMB million Yuan and RMB million Yuan, RMB million Yuan and RMB 140 million Yuan, RMB million Yuan and RMB 125 million Yuan respectively. Up to December 31, 2020, this figure reached to RMB million Yuan and RMB 139 million Yuan and our capital was RMB million Yuan and capital of per share was RMB Yuan. Following are our prediction of benefits and investment returns for future three years: Chart 1 Content 2020 2020 2020 Major business ine (RMB 1 million Yuan) 0 0 0 Major business benefits (RMB 1 million Yuan) 0 0 Other business benefits (RMB 1 million Yuan) 2 5 Total benefits (RMB 1 million 0 0 Yuan) Net benefits (RMB 1 million Yuan) 5 0 Dividable benefits of per share(RMB 1 Yuan) 5 Chart 2(See the next page) Content Formula 2020 2020 2020 Gross profit of sale (%) Gross business profit/business ine 53 50 Returns for total capital (%) Net benefits/total capital 20 Note: Our business ine went through a difficult time of decrease for several sequential fiscal years from 2020 as reason of marketing saturation with old medicines until our new products came into market in 2020. Particularly, we will have power of possessing desirable market shares and thus increasing our business ine with the issuing of Zhiqi granule. It is predicted that our business ine will be increased in the future three years. (三 ) Capital running Domestic and global markets will be linked with Chinese entrance of WTO. Our major strategic goal of capital running is to expand our productivity and improve our market shares through taking advantage of favorable governmental policy and our advanced technology, integrating together our advantages of resource, capital and researching achievement and actively entering the capital market. 1. We have adopted methods of cautious takeover and purchase to increase our product variety and add more marketing channels. We have successfully taken over and purchased some domestic pharmaceutical enterprises which are relatively advantageous with their products and then put into part of our capital for improvement of GMP, product quality and advertisement. We have promoted our market shares quickly with previously accepted products. In all, we have established a solid basis for our goal of expansion through our takeover and purchasing activities. 2. We have promoted our petition power thoroughly by means of investing more money, increasing more shares, accepting more capital and assets, cooper